pitavastatin and Seizures

The present study aimed to evaluate the neuroprotective potential of intranasally administered pitavastatin in the PTZ-induced kindling model.. Comparative in-silico study showed docking score of -4.56 and -2.86 against GABA. Our findings suggest that the intranasally administered pitavastatin is potential therapeutic approach to managing PTZ-induced kindling and associated comorbid conditions via its antioxidant, anti-inflammatory, and anticonvulsant potential. Further, pitavastatin can modulate GABA

Topics: Administration, Intranasal; Animals; Behavior, Animal; Cognitive Dysfunction; Convulsants; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Neuroprotective Agents; Oxidative Stress; Pentylenetetrazole; Quinolines; Seizures

This study was carried out to evaluate the effect of intranasal pitavastatin (PVS) on pentylenetetrazole (PTZ)-induced seizures, increasing current electroshock (ICES) seizures, and status epilepticus in mice. Intranasal PVS, 0.5 and 1.0mg/kg, showed significant increase in latency to PTZ-induced seizures and ICES seizure threshold compared to control; however, the effects were dose-dependent and were more significant at higher dose. Further, intranasal PVS (1.0mg/kg) but not intravenous PVS (50.0mg/kg) showed effective protection against PTZ-induced status epilepticus. No impairment in cognitive functions was observed following intranasal PVS (1.0mg/kg), thus making it a prospective therapeutic approach for acute seizures and status epilepticus.

Topics: Administration, Intranasal; Animals; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Neuroprotective Agents; Prospective Studies; Quinolines; Seizures; Status Epilepticus